By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Kuros Biosciences AG

Kuros Biosciences AG (0RHR.L)

LSE Currency in CHF
CHF 29.07
+CHF 0.39
+1.36%
Last Update: 17 Jul 2025, 10:19
CHF 995.58M
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
CHF 1.33 - CHF 29.37
52 Week Range

0RHR.L Stock Price Chart

Explore Kuros Biosciences AG interactive price chart. Choose custom timeframes to analyze 0RHR.L price movements and trends.

There is nothing to show.

0RHR.L Company Profile

Discover essential business fundamentals and corporate details for Kuros Biosciences AG (0RHR.L) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

24 May 2023

Employees

122.00

CEO

Christopher T. Fair

Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

0RHR.L Financial Timeline

Browse a chronological timeline of Kuros Biosciences AG corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 9 Mar 2026

Upcoming earnings on 13 Aug 2025

Earnings released on 11 Mar 2025

EPS came in at -CHF 0.11, while revenue for the quarter reached CHF 43.71M, missing expectations by -3.51%.

Earnings released on 10 Oct 2024

EPS came in at -CHF 0.01, while revenue for the quarter reached CHF 31.84M, beating expectations by +6.15%.

Earnings released on 13 Mar 2024

EPS came in at -CHF 0.24, while revenue for the quarter reached CHF 20.70M, beating expectations by +10.68%.

Earnings released on 30 Jun 2023

EPS came in at -CHF 0.14, while revenue for the quarter reached CHF 12.87M, beating expectations by +36.87%.

Earnings released on 31 Dec 2022

EPS came in at -CHF 0.32, while revenue for the quarter reached CHF 7.56M, missing expectations by -14.09%.

Earnings released on 30 Jun 2022

EPS came in at -CHF 0.11, while revenue for the quarter reached CHF 10.43M, beating expectations by +10.91%.

Earnings released on 31 Dec 2021

EPS came in at -CHF 0.23, while revenue for the quarter reached CHF 4.73M, missing expectations by -33.39%.

Earnings released on 30 Jun 2021

EPS came in at -CHF 0.00, while revenue for the quarter reached CHF 9.09M, missing expectations by -0.15%.

Stock split effective on 11 Jun 2021

Shares were split 217:200, changing the number of shares outstanding and the price per share accordingly.

Earnings released on 31 Dec 2020

EPS came in at -CHF 0.21 surpassing the estimated -CHF 0.30 by +28.79%, while revenue for the quarter reached CHF 2.74M, beating expectations by +9.76%.

0RHR.L Stock Performance

Access detailed 0RHR.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
0RHR.L
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
0RHR.L
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More